skip to main content


Series A Preferred Stock Financing of Hyalex Orthopaedics

Canaan Partners

Represented Canaan Partners in connection with a $16 million Series A Preferred Stock financing of Hyalex Orthopaedics with participation from Osage University Partners and Johnson & Johnson Innovation - JJDC. Hyalex Orthopaedics is developing a synthetic biomaterial based on technology licensed from Stanford University intended to mimic the structure and function of hyaline cartilage, which lines articulating joints at the hip, knee, shoulder and ankle. For more information click here.


Practice Areas

© Shipman & Goodwin LLP 2020. All Rights Reserved.